Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study.

Ernesto MartínJosé López-AguileraRafael Gonzalez-ManzanaresManuel AnguitaGuillermo GutiérrezAurora LuqueNick ParedesJesús OnetoJorge PereaJuan Carlos Castillo

Published in: Journal of clinical medicine (2021)

Canagliflozin therapy at discharge was associated with a lower risk of readmission for HF and a reduction in NT-ProBNP concentration in patients with diabetes after hospitalization for HF.

Keyphrases

acute heart failure
heart failure
stem cells
mesenchymal stem cells
smoking cessation